Baxter International (BAX) Competitors

Baxter International (NYSE:BAX) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

Do institutionals and insiders believe in BAX or PODD?

84.8% of Baxter International shares are held by institutional investors. 0.3% of Baxter International shares are held by insiders. Comparatively, 0.8% of Insulet shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Which has preferable earnings and valuation, BAX or PODD?

Insulet has lower revenue, but higher earnings than Baxter International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Baxter International	$15.11 billion	1.36	-$2.43 billion	-$4.88	-8.34
Insulet	$1.37 billion	13.97	$4.60 million	N/A	N/A

Does the media favor BAX or PODD?

In the previous week, Insulet had 3 more articles in the media than Baxter International. MarketBeat recorded 12 mentions for Insulet and 9 mentions for Baxter International. Insulet's average media sentiment score of 0.78 beat Baxter International's score of 0.36 indicating that Insulet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Baxter International	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insulet	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Which has more volatility & risk, BAX or PODD?

Baxter International has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Insulet has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.

Does the MarketBeat Community favor BAX or PODD?

Baxter International received 28 more outperform votes than Insulet when rated by MarketBeat users. Likewise, 67.16% of users gave Baxter International an outperform vote while only 66.48% of users gave Insulet an outperform vote.

Company	Underperform	Outperform
Baxter International	Outperform Votes 722 67.16%	Underperform Votes 353 32.84%
Insulet	Outperform Votes 694 66.48%	Underperform Votes 350 33.52%

Is BAX or PODD more profitable?

Insulet has a net margin of 0.04% compared to Baxter International's net margin of -16.34%. Baxter International's return on equity of 24.29% beat Insulet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Baxter International	-16.34%	24.29%	5.49%
Insulet	0.04%	17.29%	3.59%

Do analysts recommend BAX or PODD?

Baxter International currently has a consensus target price of $52.38, indicating a potential upside of 28.62%. Insulet has a consensus target price of $330.00, indicating a potential upside of 20.33%. Given Baxter International's higher possible upside, analysts clearly believe Baxter International is more favorable than Insulet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Baxter International	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Insulet	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46

Summary

Insulet beats Baxter International on 10 of the 17 factors compared between the two stocks.